# To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

Study · id `cardio:ct-nct06500689` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06500689](<https://clinicaltrials.gov/study/NCT06500689>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06500689

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 366 participants.

## Technical summary

Registry record NCT06500689. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-30 (actual); primary completion 2023-11-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 366 participants (enrolled count; ClinicalTrials.gov record NCT06500689, source copy `cardio:ctgov-nct06500689-2024-07-15`, retrieved 2026-10-26)
- Started: 2021-12-30 (actual) (ClinicalTrials.gov record NCT06500689, source copy `cardio:ctgov-nct06500689-2024-07-15`, retrieved 2026-10-26)
- Primary completion: 2023-11-27 (actual) (ClinicalTrials.gov record NCT06500689, source copy `cardio:ctgov-nct06500689-2024-07-15`, retrieved 2026-10-26)
- Completion: 2024-05-24 (actual) (ClinicalTrials.gov record NCT06500689, source copy `cardio:ctgov-nct06500689-2024-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06500689, source copy `cardio:ctgov-nct06500689-2024-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06500689-2024-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
- Condition: Essential Hypertension
- Intervention (Drug): Allisartan Isoproxil/Sustained-Release Indapamide
- Intervention (Drug): Allisartan Isoproxil
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 7936e5582895be72e4fc11bde9083362f90560cba03d81015f543b40fb3eefc9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
